[go: up one dir, main page]

PT2343380T - Permuta de cassetes da região variável de imunoglobulina - Google Patents

Permuta de cassetes da região variável de imunoglobulina

Info

Publication number
PT2343380T
PT2343380T PT10014128T PT10014128T PT2343380T PT 2343380 T PT2343380 T PT 2343380T PT 10014128 T PT10014128 T PT 10014128T PT 10014128 T PT10014128 T PT 10014128T PT 2343380 T PT2343380 T PT 2343380T
Authority
PT
Portugal
Prior art keywords
variable region
immunoglobulin variable
cassette exchange
region cassette
exchange
Prior art date
Application number
PT10014128T
Other languages
English (en)
Inventor
Bebbington Christopher
Luehrsen Kenneth
Yarranton Geoffrey
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36407771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2343380(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humanigen Inc filed Critical Humanigen Inc
Publication of PT2343380T publication Critical patent/PT2343380T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT10014128T 2004-11-16 2005-11-16 Permuta de cassetes da região variável de imunoglobulina PT2343380T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62858104P 2004-11-16 2004-11-16

Publications (1)

Publication Number Publication Date
PT2343380T true PT2343380T (pt) 2019-09-18

Family

ID=36407771

Family Applications (2)

Application Number Title Priority Date Filing Date
PT10014128T PT2343380T (pt) 2004-11-16 2005-11-16 Permuta de cassetes da região variável de imunoglobulina
PT191691351T PT3540062T (pt) 2004-11-16 2005-11-16 Permuta de cassete de região variável de imunoglobulina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191691351T PT3540062T (pt) 2004-11-16 2005-11-16 Permuta de cassete de região variável de imunoglobulina

Country Status (10)

Country Link
US (2) US20060134098A1 (pt)
EP (3) EP2343380B1 (pt)
JP (1) JP2008520586A (pt)
AU (1) AU2005306502B2 (pt)
CA (1) CA2587158C (pt)
DK (2) DK2343380T3 (pt)
ES (3) ES2881353T3 (pt)
PL (2) PL2343380T3 (pt)
PT (2) PT2343380T (pt)
WO (1) WO2006055778A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
CN103505728A (zh) * 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
EP2035448A4 (en) 2006-06-01 2010-11-03 Elan Pharm Inc NEUROACTIVE FRAGMENTS OF APP
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
CN101605547A (zh) 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
WO2008103475A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
PT3199180T (pt) * 2007-03-08 2022-04-01 Univ Monash Anticorpos epha3 para o tratamento de tumores sólidos
EP2236518B1 (en) * 2007-03-14 2014-08-06 Alexion Cambridge Corporation Humaneered anti-factor B antibody
BRPI0813833A2 (pt) * 2007-07-17 2015-01-06 Irm Llc Anticorpos antagonistas de receptor-1 ativado por protease (par1)
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
NZ586357A (en) 2007-11-30 2012-10-26 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009114815A1 (en) * 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
US9388510B2 (en) 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
MX2010011761A (es) 2008-04-28 2010-11-30 Kalobios Pharmaceuticals Inc Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
JP2012516897A (ja) 2009-02-04 2012-07-26 カロバイオス ファーマシューティカルズ インコーポレイティッド シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）感染の治療のための抗生物質と抗体療法との組み合わせ
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
AU2010221159B2 (en) 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
EP2432878B2 (en) * 2009-05-20 2018-05-16 Novimmune SA Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
CN102666589B (zh) 2009-10-14 2014-08-20 卡罗拜奥斯制药公司 EphA3抗体
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US9150641B2 (en) * 2009-12-22 2015-10-06 Hoffmann—La Roche Inc. Sequence dependent aggregation
RU2565539C2 (ru) 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
CA2794851A1 (en) * 2010-04-02 2011-10-06 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest
JP2014511378A (ja) 2011-02-11 2014-05-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｃｓｋ９アンタゴニスト
WO2012125733A2 (en) 2011-03-15 2012-09-20 X-Body, Inc. Antibody screening methods
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
US20130109586A1 (en) * 2011-10-05 2013-05-02 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
HUE047283T2 (hu) 2013-12-09 2020-04-28 Allakos Inc Anti-SIGLEC-8 antitestek és eljárások az alkalmazásukra
EP3110446B1 (en) 2014-02-28 2021-12-01 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
EP3157951B1 (en) * 2014-06-17 2020-05-13 Academia Sinica Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3310385A4 (en) 2015-06-17 2018-12-19 Allakos Inc. Methods and compositions for treating fibrotic diseases
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
EA201891341A1 (ru) 2015-12-04 2018-11-30 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP3512883A1 (en) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AU2018261887A1 (en) 2017-05-05 2019-12-05 Allakos Inc. Methods and compositions for treating allergic ocular diseases
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
EP3691663A4 (en) 2017-10-02 2021-08-18 Humanigen, Inc. METHODS OF TREATMENT OF TOXICITY ASSOCIATED WITH IMMUNOTHERAPIES USING A GM-CSF ANTAGONIST
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
CA3209364A1 (en) 2021-03-01 2022-09-09 Jennifer O'neil Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3742105A (en) 1970-05-05 1973-06-26 S Kuroda Method for producing a seamless tubing
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
DE68913658T3 (de) * 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1362868A3 (en) 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
JP4436457B2 (ja) * 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
AU760562B2 (en) * 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
DE60118370T2 (de) 2000-06-05 2006-12-07 Corixa Corp., Seattle Leader-anteile zur erhöhung der sekretion von rekombinanten proteinen aus einer wirtzelle
WO2002000005A1 (en) 2000-06-21 2002-01-03 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
EP2298809A3 (en) * 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1514216A4 (en) * 2002-05-20 2010-01-06 Abmaxis Inc GENERATION AND SELECTION OF A PROTEIN LIBRARY IN SILICO
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050008625A1 (en) * 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
US7981843B2 (en) * 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Also Published As

Publication number Publication date
DK3540062T3 (da) 2021-06-28
US20060134098A1 (en) 2006-06-22
AU2005306502A1 (en) 2006-05-26
US20160102152A1 (en) 2016-04-14
EP3540062A1 (en) 2019-09-18
ES2429541T3 (es) 2013-11-15
WO2006055778A2 (en) 2006-05-26
EP3540062B1 (en) 2021-05-12
EP1824987A2 (en) 2007-08-29
EP2343380B1 (en) 2019-06-12
EP1824987A4 (en) 2008-03-19
CA2587158A1 (en) 2006-05-26
EP1824987B1 (en) 2013-08-21
ES2744149T3 (es) 2020-02-21
US10919983B2 (en) 2021-02-16
CA2587158C (en) 2016-01-12
WO2006055778A3 (en) 2006-11-23
DK2343380T3 (da) 2019-09-09
PL3540062T3 (pl) 2021-12-27
JP2008520586A (ja) 2008-06-19
PT3540062T (pt) 2021-07-06
AU2005306502B2 (en) 2012-11-15
EP2343380A1 (en) 2011-07-13
ES2881353T3 (es) 2021-11-29
PL2343380T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
PT3540062T (pt) Permuta de cassete de região variável de imunoglobulina
TWI307630B (en) Immunoglobulins
TWI365746B (en) Immunoglobulins
IL183861A0 (en) Temperature compensanon
GB0426735D0 (en) The mobile e-commerce exchange
GB0417789D0 (en) Access control
GB0407231D0 (en) Variable lens
GB0423010D0 (en) Cassette
ZA200504313B (en) Cassette assembly
GB0421997D0 (en) Film
GB0511578D0 (en) No Title
GB0511580D0 (en) No title
ZA200610612B (en) Immunoglobulins
GB2410544B (en) Radiator cover
GB0302699D0 (en) Immunoglobulin
GB0417389D0 (en) No title
GB0407197D0 (en) Immunoglobulins
GB0417492D0 (en) Radiator covers
GB0513766D0 (en) Immunoglobulins
GB0405968D0 (en) Neat heat
PL1635122T3 (pl) Grzejnik
GB0423675D0 (en) Immunoglobulins
GB0407193D0 (en) Immunoglobulins
GB0401247D0 (en) Router cassette
AU2004906517A0 (en) Heat exchanger improvements